DK0848752T3 - Fremgangsmåde til rensning af vira ved chromatografi - Google Patents

Fremgangsmåde til rensning af vira ved chromatografi

Info

Publication number
DK0848752T3
DK0848752T3 DK96924954T DK96924954T DK0848752T3 DK 0848752 T3 DK0848752 T3 DK 0848752T3 DK 96924954 T DK96924954 T DK 96924954T DK 96924954 T DK96924954 T DK 96924954T DK 0848752 T3 DK0848752 T3 DK 0848752T3
Authority
DK
Denmark
Prior art keywords
pct
date
chromatography step
chromatography
viruses
Prior art date
Application number
DK96924954T
Other languages
English (en)
Inventor
Bernard Fanget
Alain Francon
Original Assignee
Aventis Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9481946&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0848752(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Pasteur filed Critical Aventis Pasteur
Application granted granted Critical
Publication of DK0848752T3 publication Critical patent/DK0848752T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/205—Rhabdoviridae, e.g. rabies virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P13/00—Preparation of nitrogen-containing organic compounds
    • C12P13/001—Amines; Imines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P13/00—Preparation of nitrogen-containing organic compounds
    • C12P13/02—Amides, e.g. chloramphenicol or polyamides; Imides or polyimides; Urethanes, i.e. compounds comprising N-C=O structural element or polyurethanes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20151—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
DK96924954T 1995-08-10 1996-07-08 Fremgangsmåde til rensning af vira ved chromatografi DK0848752T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9509851A FR2737730B1 (fr) 1995-08-10 1995-08-10 Procede de purification de virus par chromatographie
PCT/FR1996/001064 WO1997006243A1 (fr) 1995-08-10 1996-07-08 Procede de purification de virus par chromatographie

Publications (1)

Publication Number Publication Date
DK0848752T3 true DK0848752T3 (da) 2003-09-29

Family

ID=9481946

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96924954T DK0848752T3 (da) 1995-08-10 1996-07-08 Fremgangsmåde til rensning af vira ved chromatografi

Country Status (17)

Country Link
US (1) US6008036A (da)
EP (1) EP0848752B1 (da)
KR (1) KR100424337B1 (da)
CN (1) CN1090235C (da)
AT (1) ATE242317T1 (da)
AU (1) AU712490B2 (da)
BR (1) BR9609837A (da)
CA (1) CA2226312C (da)
DE (1) DE69628564T2 (da)
DK (1) DK0848752T3 (da)
EA (1) EA001414B1 (da)
ES (1) ES2197241T3 (da)
FR (1) FR2737730B1 (da)
MX (1) MX9801072A (da)
NZ (1) NZ313213A (da)
PT (1) PT848752E (da)
WO (1) WO1997006243A1 (da)

Families Citing this family (193)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1944362T3 (da) * 1997-09-05 2016-01-25 Genzyme Corp Fremgangsmåder til fremstilling af hjælpevirusfri præparater med høj titer af rekombinante AAV-vektorer
US6566118B1 (en) 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6995006B2 (en) 1997-09-05 2006-02-07 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
EP1930418B1 (en) 1998-09-04 2015-04-08 Genzyme Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
ATE332364T1 (de) * 1999-02-22 2006-07-15 Transgene Sa Verfahren zur gewinnung von purifizierter virenzuammensetzung
US6464976B1 (en) 1999-09-07 2002-10-15 Canji, Inc. Methods and compositions for reducing immune response
US6436402B1 (en) * 1999-10-15 2002-08-20 Merck & Co., Inc. Process for making human papillomavirus virus-like particles with improved properties
EP1681299B1 (en) 2000-03-27 2009-11-11 Genetics Institute, LLC Methods for purifying highly anionic proteins
EP1404428B1 (en) * 2001-06-05 2006-07-19 Genetics Institute, LLC Methods for purifying highly anionic proteins
US6833238B2 (en) 2002-01-04 2004-12-21 Applera Corporation Petal-array support for use with microplates
US20040016702A1 (en) * 2002-07-26 2004-01-29 Applera Corporation Device and method for purification of nucleic acids
CA2529053A1 (en) * 2003-06-18 2004-12-29 Onyx Pharmaceuticals, Inc. Method for purifying virus
WO2004113518A1 (en) * 2003-06-20 2004-12-29 Microbix Biosystems Inc. Improvements in virus production
US7479222B2 (en) * 2004-02-05 2009-01-20 Millipore Corporation Porous adsorptive or chromatographic media
US20050181378A1 (en) * 2004-02-18 2005-08-18 Applera Corporation Polyelectrolyte-coated size-exclusion ion-exchange particles
US20060160122A1 (en) * 2004-02-18 2006-07-20 Applera Corporation Polyelectrolyte-coated size-exclusion ion-exchange particles
US20050196856A1 (en) * 2004-02-18 2005-09-08 Applera Corporation Polyelectrolyte-coated size-exclusion ion-exchange particles
EP1718738A2 (en) * 2004-02-23 2006-11-08 Crucell Holland B.V. Virus purification methods
NZ551448A (en) * 2004-05-20 2011-02-25 Novartis Vaccines & Diagnostic Analysis of liquid chromotography eluates
JP4896021B2 (ja) 2004-05-21 2012-03-14 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド 呼吸器系病原体ワクチンのためのアルファウイルスベクター
CN101155915B (zh) * 2005-04-11 2013-12-04 克鲁塞尔荷兰公司 利用超滤进行病毒纯化
US20070111309A1 (en) * 2005-10-04 2007-05-17 Daelli Marcelo G Vero cell line adapted to grow in suspension
CN101426905B (zh) 2006-04-20 2013-03-27 惠氏公司 从细胞培养物分离纯化的水泡性口炎病毒的纯化方法
EP1878791A1 (en) * 2006-07-11 2008-01-16 Bia Separations D.O.O. Method for influenza virus purification
WO2008091283A2 (en) 2006-07-13 2008-07-31 Institute For Advanced Study Viral inhibitory nucleotide sequences and vaccines
US8481298B2 (en) 2006-09-29 2013-07-09 Ge Healthcare Bio-Sciences Ab Separation matrix for viral purification
EP2679237A1 (en) 2006-11-29 2014-01-01 Nationwide Children's Hospital Myostatin inhibition for enhancing muscle and/or improving muscle function
US9433922B2 (en) * 2007-08-14 2016-09-06 Emd Millipore Corporation Media for membrane ion exchange chromatography based on polymeric primary amines, sorption device containing that media, and chromatography scheme and purification method using the same
US20090130738A1 (en) * 2007-11-19 2009-05-21 Mikhail Kozlov Media for membrane ion exchange chromatography
US11219696B2 (en) 2008-12-19 2022-01-11 Nationwide Children's Hospital Delivery of polynucleotides using recombinant AAV9
US9415121B2 (en) 2008-12-19 2016-08-16 Nationwide Children's Hospital Delivery of MECP2 polynucleotide using recombinant AAV9
US20110293660A1 (en) 2009-02-06 2011-12-01 Bruno Rene Andre Novel method
FR2944292B1 (fr) 2009-04-08 2013-08-23 Sanofi Pasteur Procede de purification du virus rabique
HUE038451T2 (hu) 2009-08-06 2018-10-29 Hoffmann La Roche Eljárás vírus eltávolításának javítására fehérjetisztítás során
JP2013506672A (ja) 2009-10-02 2013-02-28 トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク 魚類レオウイルス免疫原性組成物
US8557253B2 (en) 2009-10-07 2013-10-15 Sanofi Pasteur Sa Stabilizing excipient for inactivated whole virus vaccine
SG184833A1 (en) 2010-04-14 2012-11-29 Emd Millipore Corp Methods of producing high titer, high purity virus stocks and methods of use thereof
KR20150023923A (ko) 2010-07-30 2015-03-05 이엠디 밀리포어 코포레이션 크로마토그래피 매질 및 방법
DE102010046817A1 (de) 2010-09-28 2012-03-29 Sartorius Stedim Biotech Gmbh Verfahren zur Abtrennung von Viren aus einem Kontaminanten enthaltenden flüssigen Medium
EP2643045A4 (en) 2010-11-23 2016-01-13 Presage Biosciences Inc THERAPEUTIC PROCESSES AND COMPOSITIONS FOR SOLID FORM DELIVERY
EP3495472B1 (en) 2011-04-21 2023-11-15 Nationwide Children's Hospital, Inc. Recombinant virus products and methods for inhibition of expression of myotilin
US10196636B2 (en) 2011-04-21 2019-02-05 Nationwide Children's Hospital, Inc. Recombinant virus products and methods for inhibition of expression of myotilin
US20130039888A1 (en) 2011-06-08 2013-02-14 Nationwide Children's Hospital Inc. Products and methods for delivery of polynucleotides by adeno-associated virus for lysosomal storage disorders
CA3106285A1 (en) 2011-07-25 2013-01-31 Nationwide Children's Hospital, Inc. Recombinant virus products and methods for inhibition of expression of dux4
WO2013078316A1 (en) 2011-11-23 2013-05-30 Nationwide Children's Hospital, Inc. Recombinant adeno-associated virus delivery of alpha-sarcoglycan polynucleotides
EP3415167B1 (en) 2012-08-01 2024-05-29 Nationwide Children's Hospital Intrathecal delivery of recombinant adeno-associated virus 9
CA2885216A1 (en) 2012-09-17 2014-03-20 The Research Institute At Nationwide Children's Hospital Compositions and methods for treating amyotrophic lateral sclerosis
CN104968403A (zh) 2012-09-17 2015-10-07 格雷斯公司 色谱介质和装置
WO2014129964A2 (en) * 2013-02-22 2014-08-28 Agency For Science, Technology And Research Chromatographic purification of virus preparations with negatively charged particles
CA2909807C (en) 2013-04-20 2023-08-08 Research Institute At Nationwide Children's Hospital Recombinant adeno-associated virus delivery of exon 2-targeted u7snrna polynucleotide constructs
EP4219727A3 (en) 2013-08-27 2023-09-06 Research Institute at Nationwide Children's Hospital Products and methods for treatment of amyotrophic lateral sclerosis
WO2015069647A1 (en) 2013-11-05 2015-05-14 The Research Institute At Nationwide Children's Hospital COMPOSITIONS AND METHODS FOR INHIBITING NF- kB AND SOD-1 TO TREAT AMYOTROPHIC LATERAL SCLEROSIS
IL230970A0 (en) 2014-02-13 2014-09-30 Univ Ramot Tilapia virus vaccines
US10047130B2 (en) 2014-03-18 2018-08-14 Washington University Methods and compositions for red-shifted chromophore substitution for optogenetic applications
JP6986444B2 (ja) 2014-08-09 2021-12-22 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル Ｄｍｄ遺伝子のエクソン５内の内部リボソーム進入部位を活性化するための方法及び材料
CN106794389A (zh) 2014-09-02 2017-05-31 Emd密理博公司 具有纳米原纤化表面特征的高表面积纤维介质
WO2016057975A2 (en) 2014-10-10 2016-04-14 Research Institute At Nationwide Children's Hospital Guided injections for aav gene transfer to muscle
WO2016073739A1 (en) 2014-11-05 2016-05-12 Research Institute At Nationwide Children's Hospital Methods and materials for producing recombinant viruses in eukaryotic microalgae
SG11201703399QA (en) 2014-12-08 2017-05-30 Emd Millipore Corp Mixed bed ion exchange adsorber
SG11201704887SA (en) 2014-12-15 2017-07-28 Univ Columbia Novel tilapia virus and uses thereof
MA41451A (fr) 2015-02-04 2017-12-12 Univ Washington Constructions anti-tau
BR112017017812A2 (pt) 2015-02-23 2018-04-10 Crispr Therapeutics Ag materiais e métodos para tratamento de hemoglobinopatias
US10017832B2 (en) 2015-08-25 2018-07-10 Washington University Compositions and methods for site specific recombination at asymmetric sites
BR112018005177A2 (pt) 2015-09-17 2018-10-09 Res Inst Nationwide Childrens Hospital métodos e materiais para terapia com gene galgt2
US20190048340A1 (en) 2015-09-24 2019-02-14 Crispr Therapeutics Ag Novel family of rna-programmable endonucleases and their uses in genome editing and other applications
JP2019507579A (ja) 2015-10-28 2019-03-22 クリスパー セラピューティクス アーゲー デュシェンヌ型筋ジストロフィーの処置のための材料および方法
WO2017077386A1 (en) 2015-11-06 2017-05-11 Crispr Therapeutics Ag Materials and methods for treatment of glycogen storage disease type 1a
SG11201804166YA (en) 2015-11-16 2018-06-28 Res Inst Nationwide Childrens Hospital Materials and methods for treatment of titin-based myopathies and other titinopaties
EP3967758A1 (en) 2015-12-01 2022-03-16 CRISPR Therapeutics AG Materials and methods for treatment of alpha-1 antitrypsin deficiency
EP3394260B1 (en) 2015-12-23 2021-02-17 CRISPR Therapeutics AG Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration
US11938193B2 (en) 2016-01-08 2024-03-26 Washington University Compositions comprising chemerin and methods of use thereof
EP3411078A1 (en) 2016-02-02 2018-12-12 Crispr Therapeutics AG Materials and methods for treatment of severe combined immunodeficiency (scid) or omenn syndrome
US20190112353A1 (en) 2016-02-18 2019-04-18 Crispr Therapeutics Ag Materials and methods for treatment of severe combined immunodeficiency (scid) or omenn syndrome
WO2017147509A1 (en) 2016-02-25 2017-08-31 Marco Colonna Compositions comprising trem2 and methods of use thereof
AU2017222653B2 (en) 2016-02-26 2023-06-01 Research Institute At Nationwide Children's Hospital Recombinant virus products and methods for inducing DUX4 exon skipping
WO2017158422A1 (en) 2016-03-16 2017-09-21 Crispr Therapeutics Ag Materials and methods for treatment of hereditary haemochromatosis
JP7253379B2 (ja) 2016-04-02 2023-04-06 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル 組織特異的発現のための改変ｕ６プロモーターシステム
CN109121395B (zh) 2016-04-15 2022-08-09 全国儿童医院研究所 腺相关病毒载体递送β-肌聚糖和微RNA-29以及肌营养不良症的治疗
MA45477A (fr) 2016-04-15 2019-02-20 Res Inst Nationwide Childrens Hospital Administration à vecteurs de virus adéno-associé de microarn-29 et micro-dystrophine pour traiter la dystrophie musculaire
EP3445388B1 (en) 2016-04-18 2024-04-17 Vertex Pharmaceuticals Incorporated Materials and methods for treatment of hemoglobinopathies
WO2017191503A1 (en) 2016-05-05 2017-11-09 Crispr Therapeutics Ag Materials and methods for treatment of hemoglobinopathies
US11427838B2 (en) 2016-06-29 2022-08-30 Vertex Pharmaceuticals Incorporated Materials and methods for treatment of myotonic dystrophy type 1 (DM1) and other related disorders
WO2018002783A1 (en) 2016-06-29 2018-01-04 Crispr Therapeutics Ag Materials and methods for treatment of friedreich ataxia and other related disorders
US11174469B2 (en) 2016-06-29 2021-11-16 Crispr Therapeutics Ag Materials and methods for treatment of Amyotrophic Lateral Sclerosis (ALS) and other related disorders
WO2018007976A1 (en) 2016-07-06 2018-01-11 Crispr Therapeutics Ag Materials and methods for treatment of pain related disorders
CN109843914B (zh) 2016-07-06 2024-03-15 沃泰克斯药物股份有限公司 用于治疗疼痛相关病症的材料和方法
WO2018007871A1 (en) 2016-07-08 2018-01-11 Crispr Therapeutics Ag Materials and methods for treatment of transthyretin amyloidosis
WO2018020323A2 (en) 2016-07-25 2018-02-01 Crispr Therapeutics Ag Materials and methods for treatment of fatty acid disorders
US20190194628A1 (en) * 2016-09-01 2019-06-27 Takeda Vaccines, Inc. Methods for producing virus for vaccine production
US11583564B2 (en) 2016-11-17 2023-02-21 Nationwide Children's Hospital, Inc. Intrathecal delivery of recombinant adeno-associated virus encoding Methyl-CpG binding protein 2
CN110191955B (zh) 2016-12-13 2024-05-31 西雅图儿童医院（Dba西雅图儿童研究所） 在体外和体内对工程化的细胞中表达的化学物质诱导的信号传导复合物进行外源性药物激活的方法
EP3585900B1 (en) 2017-02-22 2022-12-21 CRISPR Therapeutics AG Materials and methods for treatment of spinocerebellar ataxia type 2 (sca2) and other spinocerebellar ataxia type 2 protein (atxn2) gene related conditions or disorders
US20200040061A1 (en) 2017-02-22 2020-02-06 Crispr Therapeutics Ag Materials and methods for treatment of early onset parkinson's disease (park1) and other synuclein, alpha (snca) gene related conditions or disorders
JP2020508056A (ja) 2017-02-22 2020-03-19 クリスパー・セラピューティクス・アクチェンゲゼルシャフトＣＲＩＳＰＲ Ｔｈｅｒａｐｅｕｔｉｃｓ ＡＧ 遺伝子編集のための組成物および方法
EP3585898A1 (en) 2017-02-22 2020-01-01 CRISPR Therapeutics AG Materials and methods for treatment of spinocerebellar ataxia type 1 (sca1) and other spinocerebellar ataxia type 1 protein (atxn1) gene related conditions or disorders
EP3585899A1 (en) 2017-02-22 2020-01-01 CRISPR Therapeutics AG Materials and methods for treatment of primary hyperoxaluria type 1 (ph1) and other alanine-glyoxylate aminotransferase (agxt) gene related conditions or disorders
EP3420076B1 (en) 2017-03-06 2024-02-21 Guangzhou Realbenefitspot Pharmaceutical Co., Ltd. Methods of producing and characterizing virus vaccine and virus vaccine composition
CN108524929B (zh) * 2017-03-06 2019-05-07 广州瑞贝斯药业有限公司 一种狂犬病疫苗的生产方法
EP4382183A2 (en) 2017-03-06 2024-06-12 Guangzhou Realbenefitspot Pharmaceutical Co., Ltd. Methods of producing and characterizing virus vaccine and virus vaccine composition
WO2019012336A2 (en) 2017-03-17 2019-01-17 Newcastle University ADENO-ASSOCIATED VIRAL VECTOR DELIVERY OF A MICRO-DYSTROPHIN FRAGMENT FOR TREATING MUSCLE DYSTROPHY
RS64299B1 (sr) 2017-03-17 2023-07-31 Res Inst Nationwide Childrens Hospital Isporuka adeno asociranog virusnog vektora mikrodistrofina specifičnog za mišiće za lečenje mišićne distrofije
US20180325955A1 (en) 2017-05-12 2018-11-15 Crispr Therapeutics Ag Materials and methods for engineering cells and uses thereof in immuno-oncology
EP3652324A1 (en) 2017-07-08 2020-05-20 Genethon Treatment of spinal muscular atrophy
BR112020007502A2 (pt) 2017-10-17 2020-10-06 Crispr Therapeutics Ag composições e métodos para edição gênica para hemofilia a
EP3697915A4 (en) 2017-10-18 2021-12-08 Research Institute at Nationwide Children's Hospital ADENO-ASSOCIATED VIRUS VECTOR ADMINISTRATION OF MUSCLE SPECIFIC MICRODYSTROPHIN FOR THE TREATMENT OF MUSCLE DYSTROPHY
EP3697916A4 (en) 2017-10-20 2021-08-11 Research Institute at Nationwide Children's Hospital METHODS AND MATERIALS FOR NT-3 GENE THERAPY
EP3701029A1 (en) 2017-10-26 2020-09-02 Vertex Pharmaceuticals Incorporated Materials and methods for treatment of hemoglobinopathies
WO2019094253A1 (en) 2017-11-08 2019-05-16 Avexis Inc. Means and method for preparing viral vectors and uses of same
EP3707256A1 (en) 2017-11-09 2020-09-16 CRISPR Therapeutics AG Self-inactivating (sin) crispr/cas or crispr/cpf1 systems and uses thereof
EP3714055A1 (en) 2017-11-21 2020-09-30 CRISPR Therapeutics AG Materials and methods for treatment of autosomal dominant retinitis pigmentosa
JP2021506251A (ja) 2017-12-14 2021-02-22 クリスパー セラピューティクス アーゲー 新規ｒｎａプログラム可能エンドヌクレアーゼ系、ならびにゲノム編集および他の適用におけるその使用
WO2019123430A1 (en) 2017-12-21 2019-06-27 Casebia Therapeutics Llp Materials and methods for treatment of usher syndrome type 2a and/or non-syndromic autosomal recessive retinitis pigmentosa (arrp)
EP3728594A1 (en) 2017-12-21 2020-10-28 CRISPR Therapeutics AG Materials and methods for treatment of usher syndrome type 2a
MA51637A (fr) 2018-01-12 2020-11-18 Bayer Healthcare Llc Compositions et méthodes pour l'édition génique par ciblage de la transferrine
MA51788A (fr) 2018-02-05 2020-12-16 Vertex Pharma Substances et méthodes pour traiter des hémoglobinopathies
WO2019150196A1 (en) 2018-02-05 2019-08-08 Crispr Therapeutics Ag Materials and methods for treatment of hemoglobinopathies
EP3752616A1 (en) 2018-02-16 2020-12-23 CRISPR Therapeutics AG Compositions and methods for gene editing by targeting fibrinogen-alpha
WO2019183150A1 (en) 2018-03-19 2019-09-26 Casebia Therapeutics Limited Liability Partnership Novel rna-programmable endonuclease systems and uses thereof
WO2019204668A1 (en) 2018-04-18 2019-10-24 Casebia Therapeutics Limited Liability Partnership Compositions and methods for knockdown of apo(a) by gene editing for treatment of cardiovascular disease
AU2019260687B2 (en) 2018-04-27 2022-09-22 Seattle Children's Hospital (dba Seattle Children's Research Institute) Rapamycin resistant cells
KR20210018919A (ko) 2018-06-08 2021-02-18 노파르티스 아게 약물 산물 효능을 측정하기 위한 세포-기반 분석
GB201809588D0 (en) 2018-06-12 2018-07-25 Univ Bristol Materials and methods for modulating intraocular and intracranial pressure
AU2019288291A1 (en) 2018-06-18 2021-01-21 Research Institute At Nationwide Children's Hospital Recombinant adeno-associated virus products and methods for treating dystroglycanopathies and laminin-deficient muscular dystrophies
BR112020025995A2 (pt) 2018-06-18 2021-03-23 Research Institute At Nationwide Children's Hospital administração de microdistrofina músculo-específica por vetor de vírus adeno-associado para tratar a distrofia muscular
US20210277362A1 (en) 2018-06-29 2021-09-09 Research Institute At Nationwide Children's Hospital Recombinant adeno-associated virus products and methods for treating limb girdle muscular dystrophy 2a
JP2021534794A (ja) 2018-08-29 2021-12-16 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル 変異型ｇａｒｓタンパク質の発現を阻害するための生成物および方法
WO2020081843A1 (en) 2018-10-17 2020-04-23 Casebia Therapeutics Limited Liability Partnership Compositions and methods for delivering transgenes
JP2022511776A (ja) 2018-11-30 2022-02-01 ノバルティス アーゲー Ａａｖウイルスベクター及びその使用
JP2022516010A (ja) 2018-12-21 2022-02-24 ジェネトン 遺伝子療法ベクターのための発現カセット
WO2020142479A1 (en) 2018-12-31 2020-07-09 Research Institute At Nationwide Children's Hospital Dux4 rna silencing using rna targeting crispr-cas13b
TW202043466A (zh) 2019-01-25 2020-12-01 德商百靈佳殷格翰國際股份有限公司 編碼ccl21之重組棒狀病毒
JP2022519597A (ja) 2019-02-04 2022-03-24 リサーチ・インスティチュート・アット・ネーションワイド・チルドレンズ・ホスピタル Ｃｌｎ６ポリヌクレオチドのアデノ随伴ウイルス送達
BR112021015285A2 (pt) 2019-02-04 2021-10-05 Research Institute At Nationwide Children's Hospital Entrega de vírus adenoassociado de polinucleotídeo cln3
SG11202108357PA (en) 2019-02-15 2021-08-30 Crispr Therapeutics Ag Gene editing for hemophilia a with improved factor viii expression
EP3930765A1 (en) 2019-02-26 2022-01-05 Research Institute at Nationwide Children's Hospital Adeno-associated virus vector delivery of b-sarcoglycan and the treatment of muscular dystrophy
AU2020239225A1 (en) 2019-03-12 2021-09-30 Bayer Healthcare Llc Novel high fidelity RNA-programmable endonuclease systems and uses thereof
CA3137080A1 (en) 2019-04-15 2020-10-22 Sanford Research Gene therapy for treating or preventing visual effects in batten disease
EP3966327A1 (en) 2019-05-08 2022-03-16 Vertex Pharmaceuticals Incorporated Crispr/cas all-in-two vector systems for treatment of dmd
WO2020236351A1 (en) 2019-05-17 2020-11-26 Research Institute At Nationwide Children's Hospital Improved delivery of gene therapy vectors to retinal cells using a glycoside hydrolase enzyme
US20200407729A1 (en) 2019-06-28 2020-12-31 Crispr Therapeutics Ag Materials and methods for controlling gene editing
JP2022541070A (ja) 2019-07-25 2022-09-21 ノバルティス アーゲー 調節可能な発現系
KR20220092489A (ko) 2019-08-21 2022-07-01 더 리서치 인스티튜트 앳 네이션와이드 칠드런스 하스피탈 알파-사코글리칸의 아데노 관련 바이러스 벡터 전달 및 근위축증 치료
CA3158286A1 (en) 2019-10-18 2021-04-22 Research Institute At Nationwide Children's Hospital Gene therapy targeting cochlear cells
JP2022552014A (ja) 2019-10-18 2022-12-14 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル Ｉｒｆ２ｂｐｌ遺伝子の変異に関連する障害の治療のための材料および方法
AU2020385387A1 (en) 2019-11-22 2022-06-02 Fondazione Irccs Ca' Granda Ospedale Maggiore Foliclinico Materials and methods for treatment of disorders associated with the IGHMBP2 gene
AU2020408225A1 (en) 2019-12-20 2022-07-14 Research Institute At Nationwide Children's Hospital Optimized gene therapy for targeting muscle in muscle diseases
AU2021224186A1 (en) 2020-02-18 2022-09-08 Research Institute At Nationwide Children's Hospital AAV-mediated targeting of mirna in the treatment of X-linked disorders
US20230151390A1 (en) 2020-04-14 2023-05-18 Genethon Vectors for the treatment of acid ceramidase deficiency
BR112022025586A2 (pt) 2020-06-15 2023-03-07 Res Inst Nationwide Childrens Hospital Liberação de vetor de vírus adenoassociado para distrofias musculares
WO2022018638A1 (en) 2020-07-21 2022-01-27 Crispr Therapeutics Ag Genome-editing compositions and methods to modulate faah for treatment of neurological disorders
TW202227634A (zh) 2020-09-08 2022-07-16 美商薩羅塔治療公司 表現γ—肌聚醣之腺相關病毒載體之全身性遞送及肌肉失養症之治療
AU2021345112A1 (en) 2020-09-15 2023-04-27 Research Institute At Nationwide Children's Hospital Aav-mediated homology-independent targeted integration gene editing for correction of diverse dmd mutations in patients with muscular dystrophy
CN116590346B (zh) * 2020-09-15 2024-05-14 上海药明巨诺生物医药研发有限公司 一种慢病毒载体纯化方法
JP2023543029A (ja) 2020-09-28 2023-10-12 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル 筋ジストロフィーの治療のための製品及び方法
US20220290136A1 (en) 2020-09-30 2022-09-15 Crispr Therapeutics Ag Materials and methods for treatment of amyotrophic lateral sclerosis
RU2748475C1 (ru) * 2020-11-02 2021-05-26 Федеральное государственное бюджетное учреждение "Федеральный центр охраны здоровья животных" (ФГБУ "ВНИИЗЖ") Способ спектрометрического определения концентрации рибонуклеопротеина вируса бешенства по оценке количества молекул вирусной РНК в сырье для антирабических вакцин
IL303230A (en) 2020-11-30 2023-07-01 Res Inst Nationwide Childrens Hospital Preparations and methods for the treatment of facial-shoulder-arm muscle atrophy
EP4263829A1 (en) 2020-12-17 2023-10-25 Vertex Pharmaceuticals Incorporated Compositions and methods for editing beta-globin for treatment of hemaglobinopathies
WO2022164860A1 (en) 2021-01-27 2022-08-04 Research Institute At Nationwide Children's Hospital Materials and methods for the treatment of lysosomal acid lipase deficiency (lal-d)
AU2022216260A1 (en) 2021-02-03 2023-08-17 Research Institute At Nationwide Children's Hospital Compositions and methods for treating disease associated with dux4 overexpression
WO2022170038A1 (en) 2021-02-05 2022-08-11 Amicus Therapeutics, Inc. Adeno-associated virus delivery of cln3 polynucleotide
AU2022229489A1 (en) 2021-03-04 2023-08-31 Research Institute At Nationwide Children's Hospital Products and methods for treatment of dystrophin-based myopathies using crispr-cas9 to correct dmd exon duplications
WO2022188797A1 (en) 2021-03-09 2022-09-15 Huigene Therapeutics Co., Ltd. Engineered crispr/cas13 system and uses thereof
US20240189452A1 (en) 2021-04-13 2024-06-13 Research Institute At Nationwide Children's Hospital Recombinant Adeno-Associated Virus Encoding Methyl-CPG Binding Protein 2 for Treating PITT Hopkins Syndrome VIA Intrathecal Delivery
US20240200066A1 (en) 2021-04-23 2024-06-20 Research Institute At Nationwide Children's Hospital Products and methods for treating muscular dystrophy
EP4341413A1 (en) 2021-05-17 2024-03-27 Sarepta Therapeutics, Inc. Production of recombinant aav vectors for treating muscular dystrophy
EP4108263A3 (en) 2021-06-02 2023-03-22 Research Institute at Nationwide Children's Hospital Recombinant adeno-associated virus products and methods for treating limb girdle muscular dystrophy 2a
KR20240021218A (ko) 2021-06-11 2024-02-16 바이엘 악티엔게젤샤프트 신규 유형 v rna 프로그래밍가능 엔도뉴클레아제 시스템
EP4101928A1 (en) 2021-06-11 2022-12-14 Bayer AG Type v rna programmable endonuclease systems
WO2023283962A1 (en) 2021-07-16 2023-01-19 Huigene Therapeutics Co., Ltd. Modified aav capsid for gene therapy and methods thereof
CA3228365A1 (en) 2021-08-11 2023-02-16 Solid Biosciences Inc. Treatment of muscular dystrophy
EP4144841A1 (en) 2021-09-07 2023-03-08 Bayer AG Novel small rna programmable endonuclease systems with impoved pam specificity and uses thereof
WO2023042104A1 (en) 2021-09-16 2023-03-23 Novartis Ag Novel transcription factors
AU2022360382A1 (en) 2021-10-07 2024-05-09 Research Institute At Nationwide Children's Hospital Products and methods for myelin protein zero silencing and treating cmt1b disease
WO2023060233A1 (en) 2021-10-08 2023-04-13 Amicus Therapeutics, Inc. Biomarkers for lysosomal storage diseases
EP4219726A1 (en) 2021-10-15 2023-08-02 Research Institute at Nationwide Children's Hospital Self-complementary adeno-associated virus vector and its use in treatment of muscular dystrophy
JP2023081369A (ja) 2021-11-30 2023-06-09 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル 自己相補的アデノ随伴ウイルスベクター及び筋ジストロフィーの治療におけるその使用
EP4198047A1 (en) 2021-12-16 2023-06-21 Genethon Fukutin related protein gene transfer increase using modified itr sequences
EP4198134A1 (en) 2021-12-16 2023-06-21 Genethon Gamma-sarcoglycan gene transfer increase using modified itr sequences
EP4198046A1 (en) 2021-12-16 2023-06-21 Genethon Alpha-sarcoglycan gene transfer increase using modified itr sequences
EP4198048A1 (en) 2021-12-16 2023-06-21 Genethon Calpain-3 gene transfer increase using modified itr sequences
WO2023122669A1 (en) 2021-12-21 2023-06-29 Research Institute At Nationwide Children's Hospital Materials and methods for the treatment of limb girdle muscular dystrophy
WO2023118068A1 (en) 2021-12-23 2023-06-29 Bayer Aktiengesellschaft Novel small type v rna programmable endonuclease systems
WO2023168400A2 (en) 2022-03-03 2023-09-07 Research Institute At Nationwide Children's Hospital Materials and methods for the treatment of eif2b5 mutations and diseases resulting therefrom
WO2023196818A1 (en) 2022-04-04 2023-10-12 The Regents Of The University Of California Genetic complementation compositions and methods
WO2023214346A1 (en) 2022-05-06 2023-11-09 Novartis Ag Novel recombinant aav vp2 fusion polypeptides
WO2023240177A1 (en) 2022-06-08 2023-12-14 Research Instiitute At Nationwide Children's Hospital Products and methods for treating diseases or conditions associated with mutant or pathogenic kcnq3 expression
WO2023237587A1 (en) 2022-06-10 2023-12-14 Bayer Aktiengesellschaft Novel small type v rna programmable endonuclease systems
WO2024011115A1 (en) 2022-07-06 2024-01-11 Research Institute At Nationwide Children's Hospital Adeno-associated virus delivery of cln1 polynucleotide
WO2024035782A1 (en) 2022-08-10 2024-02-15 Aav Gene Therapeutics, Inc. Aav-mediated intramuscular delivery of insulin
WO2024081706A1 (en) 2022-10-11 2024-04-18 Research Institute At Nationwide Children's Hospital Adeno-associated virus delivery to treat spinal muscular atrophy with respiratory distress type 1 (smard1) and charcot-marie-tooth type 2s (cmt2s)
WO2024092126A1 (en) 2022-10-27 2024-05-02 Cargo Therapeutics, Inc. Compositions and methods for improved immunotherapies
WO2024129743A2 (en) 2022-12-13 2024-06-20 Bluerock Therapeutics Lp Engineered type v rna programmable endonucleases and their uses

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1441767A (fr) * 1965-04-30 1966-06-10 Rohm & Haas élimination des virus au cours des processus de collecte ou de transfusion du sang
US4162192A (en) * 1978-09-28 1979-07-24 Juridical Foundation Method for purification of HBs antigen
US4525349A (en) * 1981-12-29 1985-06-25 Societe Anonyme Dite: Institut Merueux Process for the large-scale production of a vaccine against poliomyelitis and the resulting vaccine
US4664912A (en) * 1984-10-01 1987-05-12 Wiktor Tadeusz J Process for the large scale production of rabies vaccine
EP0812200B1 (en) * 1993-07-09 2002-02-27 Avant Immunotherapeutics, Inc. Protein purification
US5837520A (en) * 1995-03-07 1998-11-17 Canji, Inc. Method of purification of viral vectors

Also Published As

Publication number Publication date
NZ313213A (en) 1999-03-29
ATE242317T1 (de) 2003-06-15
CN1199419A (zh) 1998-11-18
AU6496496A (en) 1997-03-05
ES2197241T3 (es) 2004-01-01
EA199800159A1 (ru) 1998-08-27
EA001414B1 (ru) 2001-02-26
CA2226312C (fr) 2011-11-08
EP0848752B1 (fr) 2003-06-04
US6008036A (en) 1999-12-28
KR100424337B1 (ko) 2004-06-24
DE69628564T2 (de) 2004-05-13
WO1997006243A1 (fr) 1997-02-20
PT848752E (pt) 2003-10-31
KR19990036328A (ko) 1999-05-25
BR9609837A (pt) 1999-03-09
FR2737730B1 (fr) 1997-09-05
FR2737730A1 (fr) 1997-02-14
CA2226312A1 (fr) 1997-02-20
DE69628564D1 (de) 2003-07-10
MX9801072A (es) 1998-04-30
EP0848752A1 (fr) 1998-06-24
AU712490B2 (en) 1999-11-11
CN1090235C (zh) 2002-09-04

Similar Documents

Publication Publication Date Title
DK0848752T3 (da) Fremgangsmåde til rensning af vira ved chromatografi
PT828717E (pt) Metodo de preparacao de 3-haloalquil-1h-pirazoles
ATE343175T1 (de) Dateitransfersystem, vorrichtung, verfahren und computerlesbares medium, das ein dateitransferprogramm speichert
DK0868437T3 (da) Fremgangsmåde til fremstilling af hyaluronsyrefraktion med et lavt polydispersionsindeks
AU3397795A (en) A method for production of ethyl alcohol
DK0894091T3 (da) Fremgangsmåde til oprensning af et protein fra en proteinholdig opløsning
EP0727226A3 (de) Entfernen von Viren durch Ultrafiltration aus Proteinlösungen
IL122606A0 (en) (S)-hydroxy-nitrile-lyase
SE8902919D0 (sv) Anvaendning av zeoliter som adsorbenter av detergenter i biokemiska/biotekniska system och processer
DK0484464T3 (da) Fremgangsmåde til rensning af proteiner
DK0725042T3 (da) Fremgangsmåde, som gør brug af fikserede kulturer, til behandling af udledningsvand på biofiltre eller andre indretninger
SE9600086D0 (sv) New manufacturing process
AU7629196A (en) Method for purifying dimethyl sulphoxide (dmso)
ES2133796T3 (es) Aparato y procedimiento de transferencia de calor por intercambio de calor mediante generador-absorbedor, y su empleo en una bomba de calor.
DE69804970D1 (de) Ionenaustauschermembran
MX9602901A (es) Aparato de transferencia de calor con intercambio de calor con generador-absorcion y metodo que usa un licor intermedio y el uso del mismo en una bomba de calor de absorcion.
DK0937094T3 (da) Fremgangsmåde til fremstilling af ivermectin
DE59611353D1 (de) Transketolase-verwandtes protein
DK0891322T3 (da) Dimethylsubstituerede cyclohexandienderivater
MX27019A (es) Procedimiento de la realizacion de un sistema modular utilizable en particular en alta mar.
MX9601470A (es) Aparato de transferencia de calor mediante intercambio de calor entre generador-absorbedor y metodo y uso del mismo en una bomba de calor.
ATE219512T1 (de) Rinderovarzellinie (frov) zur virusvermehrung
AU2001272624A1 (en) Method and system for limiting the possibility of transforming data designed to constitute, in particular pre-payment tokens
ES1027521U (es) Placas de forjado.